About maravai lifesciences holdings inc - MRVI
Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.
MRVI At a Glance
Maravai Lifesciences Holdings, Inc.
10770 Wateridge Circle
San Diego, California 92121
| Phone | 1-858-546-0004 | Revenue | 185.74M | |
| Industry | Biotechnology | Net Income | -130,773,000.00 | |
| Sector | Health Technology | Employees | 435 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MRVI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.526 |
| Price to Book Ratio | 2.224 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -21.888 |
| Enterprise Value to Sales | 4.185 |
| Total Debt to Enterprise Value | 0.469 |
MRVI Efficiency
| Revenue/Employee | 426,995.402 |
| Income Per Employee | -300,627.586 |
| Receivables Turnover | 7.285 |
| Total Asset Turnover | 0.209 |
MRVI Liquidity
| Current Ratio | 6.596 |
| Quick Ratio | 5.694 |
| Cash Ratio | 4.829 |
MRVI Profitability
| Gross Margin | 16.954 |
| Operating Margin | -51.677 |
| Pretax Margin | -126.505 |
| Net Margin | -70.405 |
| Return on Assets | -14.703 |
| Return on Equity | -48.644 |
| Return on Total Capital | -22.661 |
| Return on Invested Capital | -20.904 |
MRVI Capital Structure
| Total Debt to Total Equity | 171.725 |
| Total Debt to Total Capital | 63.198 |
| Total Debt to Total Assets | 47.329 |
| Long-Term Debt to Equity | 165.038 |
| Long-Term Debt to Total Capital | 60.737 |